MA29238B1 - Synthese de taurine, production et utilisation de celle-ci comme medicament - Google Patents

Synthese de taurine, production et utilisation de celle-ci comme medicament

Info

Publication number
MA29238B1
MA29238B1 MA30110A MA30110A MA29238B1 MA 29238 B1 MA29238 B1 MA 29238B1 MA 30110 A MA30110 A MA 30110A MA 30110 A MA30110 A MA 30110A MA 29238 B1 MA29238 B1 MA 29238B1
Authority
MA
Morocco
Prior art keywords
taurine
production
medicinal product
salts
quantitative
Prior art date
Application number
MA30110A
Other languages
English (en)
Inventor
Magd Ahmed Kotb Abdalla
Original Assignee
Magd Ahmed Kotb Abdalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magd Ahmed Kotb Abdalla filed Critical Magd Ahmed Kotb Abdalla
Publication of MA29238B1 publication Critical patent/MA29238B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA VOIE LA PLUS IMPORTANTE, DU POINT DE VUE QUANTITATIF, D'EXCRÉTION DU CHOLESTÉROL CHEZ LES MAMMIFÈRES EST LA FORMATION DE SELS BILIAIRES (BASES CONJUGUÉES DES ACIDES BILIAIRES). LA PLUPART DES SELS BILIAIRES SONT SYNTHÉTISÉS ET SÉCRÉTÉS SOUS FORME DE CONJUGUÉS DE GLYCINE OU DE TAURINE. LA TAURINE (ACIDE 2 AMINOÉTHYL SULPHONIQUE), QUI EST PRODUITE NATURELLEMENT PAR LES CELLULES HÉPATIQUES ET LES CELLULES DU SYSTÈME NERVEUX CENTRAL, EST NEUROPROTECTRICE ET CONSTITUE UN HYPOCHOLESTÉROLÉMIANT PRATIQUEMENT DÉPOURVU D'EFFETS SECONDAIRES.
MA30110A 2005-01-05 2007-07-26 Synthese de taurine, production et utilisation de celle-ci comme medicament MA29238B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05

Publications (1)

Publication Number Publication Date
MA29238B1 true MA29238B1 (fr) 2008-02-01

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30110A MA29238B1 (fr) 2005-01-05 2007-07-26 Synthese de taurine, production et utilisation de celle-ci comme medicament

Country Status (15)

Country Link
EP (1) EP1844006A2 (fr)
JP (1) JP2008526789A (fr)
KR (1) KR20070091198A (fr)
CN (1) CN101146767A (fr)
AP (1) AP2007004084A0 (fr)
AU (1) AU2005324199A1 (fr)
BR (1) BRPI0519606A2 (fr)
CA (1) CA2593563A1 (fr)
EA (1) EA200701434A1 (fr)
IL (1) IL184221A0 (fr)
MA (1) MA29238B1 (fr)
MX (1) MX2007008196A (fr)
NO (1) NO20074937A (fr)
TN (1) TNSN07226A1 (fr)
WO (1) WO2006072259A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130590T1 (en) 2007-11-30 2013-08-31 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (zh) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 一种牛磺酸的制备方法
CN106728405A (zh) * 2016-11-15 2017-05-31 陈思文 一种牛磺酸和水溶性茶多酚复方组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (ja) * 1981-12-22 1983-08-19 Junichi Azuma 心不全治療剤
JPH08208464A (ja) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd 高脂血症の治療及び予防薬
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (zh) * 2000-06-30 2002-03-20 张永春 牛磺酸合锌的生产工艺
CN1268733C (zh) * 2004-07-20 2006-08-09 刘辉 牛磺酸功能啤酒及其生产工艺

Also Published As

Publication number Publication date
CN101146767A (zh) 2008-03-19
KR20070091198A (ko) 2007-09-07
AP2007004084A0 (en) 2007-08-31
CA2593563A1 (fr) 2006-07-13
EA200701434A1 (ru) 2008-10-30
WO2006072259A2 (fr) 2006-07-13
MX2007008196A (es) 2008-02-22
JP2008526789A (ja) 2008-07-24
TNSN07226A1 (en) 2008-11-21
BRPI0519606A2 (pt) 2009-02-25
NO20074937A (no) 2007-09-28
IL184221A0 (en) 2008-12-29
AU2005324199A1 (en) 2006-07-13
EP1844006A2 (fr) 2007-10-17
WO2006072259A3 (fr) 2007-10-04

Similar Documents

Publication Publication Date Title
DE69628290T2 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
US5700830A (en) Use of nitric oxide-releasing agents for reducing metastasis risk
EP1730163A4 (fr) Sels pharmaceutiques de l&#39;acide 3- o-(3&#39;,3&#39;-dimethylsuccinyl)betulinique
ES2331832T3 (es) Nuevo derivado de acido lipoico y su uso.
EP3210633A3 (fr) Compositions et leurs utilisations dirigées vers l&#39;huntingtine
DE69925830D1 (de) Peg-lhrh analog konjugate
Metzner et al. Serotonin, l‐tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1
WO1997030170A1 (fr) Composition pour la transfection de cellules eucaryotes superieures
MA29238B1 (fr) Synthese de taurine, production et utilisation de celle-ci comme medicament
ES2874862T3 (es) Extracto antiinflamatorio de Boswellia frereana
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
EP2110135A3 (fr) Composition pharmaceutique pour traiter la dépression et son procédé de préparation
EP1275646A4 (fr) Derives indolylpyrrole et inhibiteurs de mort cellulaire
EP1152002A4 (fr) Derives de pyrrole et inhibiteurs de la mort cellulaire
BRPI0509468A (pt) 1,3,4-oxadiazol-2-onas como modulares de ppar delta e usos das mesmas
BR9915019A (pt) Derivados de propanolamina ligados com ácido biliar para o tratamento de distúrbios do metabolismo de lipìdeos
NO20073132L (no) Fremstilling av proteiner
EP1731146A4 (fr) Pr vention de et mesure contre la maladie mitochondriale
JP2017071600A (ja) くすぶり炎症抑制剤
EP1968606A4 (fr) Préparation de sels pharmaceutiques de l&#39;acide 3-o-(3&#39;,3&#39;-diméthylsuccinyl)bétulinique
Wells et al. Tris and the ready production of drug‐fatty acyl conjugates
TR200200224T2 (tr) Böbrek bozukluğu ve hastalıklarının önlenmesi ve tedavisi için bileşim
WO2012061165A2 (fr) Procédés et compositions d&#39;amélioration de propriétés admet
FR2868776B1 (fr) Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l&#39;ivabradine et de ses sels d&#39;addition a un acide pharmaceutiquement acceptable
EP2272537A3 (fr) Sels de conjuguées de médicaments psychotropiques et procédés pour leur synthèse